FCMI
PTGX icon

Foresite Capital Management III’s Protagonist Therapeutics PTGX Stock Holding History

Foresite Capital Management III’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-346,281
Closed -$4.44M – 31
2017
Q1 		$4.44M Hold
346,281
– – 1.7% 12
2016
Q4 		$7.62M Hold
346,281
– – 3.31% 9
2016
Q3 		$6.29M Buy
+346,281
New +$4.73M 2.94% 9

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Foresite Capital Management III's PTGX Position: Q2 2017 in Review

Foresite Capital Management III sold out of Protagonist Therapeutics (PTGX) in Q2 2017, closing a stake of 346,281 shares — an estimated $4.44M sold.

Foresite Capital Management III first reported a position in PTGX in Q3 2016 and held it in 3 quarters. The position peaked at $7.62M in Q4 2016. 43 funds tracked by Wall St. Rank hold PTGX as of Q2 2017.

  • Foresite Capital Management III reported no remaining Protagonist Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Foresite Capital Management III sold 346,281 Protagonist Therapeutics shares in Q2 2017, an estimated $4.44M.
  • Foresite Capital Management III first reported a position in Protagonist Therapeutics in Q3 2016 and held it in 3 quarters.
  • Foresite Capital Management III's Protagonist Therapeutics position peaked at $7.62M in Q4 2016.
  • 43 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2017.

Based on Foresite Capital Management III's 13F filing for Q2 2017, filed 14 Aug 2017.